Alvotech - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ALVO Nasdaq 2836 www.alvotech.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alvotech

Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024 - Dec 23rd, 2024 9:00 am
Exploring Three High Growth Tech Stocks in the United States - Dec 16th, 2024 2:09 pm
Alvotech Third Quarter 2024 Earnings: US$0.041 loss per share (vs US$0.81 loss in 3Q 2023) - Nov 16th, 2024 12:20 pm
Alvotech (ALVO) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Advancements - Nov 15th, 2024 7:07 am
Alvotech Reports Financial Results for the First Nine Months of 2024 - Nov 13th, 2024 9:05 pm
Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024 - Nov 7th, 2024 1:00 pm
European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab) - Nov 4th, 2024 12:00 pm
Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET - Oct 30th, 2024 12:30 pm
Exploring High Growth Tech Stocks In The US October 2024 - Oct 28th, 2024 2:07 pm
Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024 - Oct 25th, 2024 12:00 pm
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab) - Oct 22nd, 2024 11:00 am
European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva® - Oct 10th, 2024 9:01 am
High Growth Tech Stocks in the United States to Watch - Sep 27th, 2024 2:04 pm
Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio® - Sep 25th, 2024 9:01 am
Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - Aug 26th, 2024 1:15 pm
Alvotech Second Quarter 2024 Earnings: EPS: US$0.25 (vs US$0.83 in 2Q 2023) - Aug 19th, 2024 10:22 am
Alvotech's (NASDAQ:ALVO) biggest owners are private equity firms who got richer after stock soared 19% last week - Aug 17th, 2024 12:41 pm
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024 - Aug 15th, 2024 8:15 pm
European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept) - Aug 15th, 2024 8:30 am
Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET - Aug 1st, 2024 8:02 pm